Loading clinical trials...

Diesel Exhaust Particles and Leukotriene Production | Clinical Trials | Clareo Health

WITHDRAWN

Diesel Exhaust Particles and Leukotriene Production

NCT00915447•University of California, Los Angeles

Summary

The purpose of this study is to measure the effects of allergens and/or diesel exhaust particles in the nose to learn more about allergic responses in individuals with cat allergic rhinitis.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18 to 65 years old.
•2. Positive prick (epicutaneous) skin test to standardized cat with a wheal equal to or greater than 3 mm and with a surrounding flare.
•3. Ability to give informed consent.

Exclusion Criteria

•1. Pregnancy or breast-feeding. (Pregnancy and the period during breast feeding can affect nasal congestion and be a confounder in this regard.)
•2. Systemic corticosteroid use within the previous three months or anytime during the challenge protocol.
•3. Topical nasal corticosteroid use within the past month or anytime during the challenge protocol.
•4. Systemic antihistamines or decongestant use within past two weeks or anytime during the trial.
•5. Chronic sinusitis or chronic non-allergic rhinitis.
•6. Use of reserpine.
•7. Cigarette smoking within the past year or during the challenge protocol
•8. Use of topical nasal antihistamines, chromoglycolates (chromolyn, Cromlon®), decongestants or non-steroidal anti-inflammatory agents (NSIADS) within the preceding week or anytime during the challenge protocol.
•9. Present or treatment within the past 10 years with allergy immunotherapy (injections).
•10. Present or past treatment with anti-IgE therapy.
+4 more criteria

Locations (1)

University of California, Los Angeles

Los Angeles, California, United States

Key Dates

Start Date

April 1, 2008

Primary Completion Date

April 11, 2013

Completion Date

April 11, 2013

Last Updated

January 23, 2019

Conditions

Allergic Rhinitis

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

NCT06732414

Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a

View study

RECRUITINGNA

Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO"

NCT05494346

Acute RhinitisNasal Obstruction+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Diesel Exhaust Particles and Leukotriene Production

Inclusion Criteria

Exclusion Criteria

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO"

Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT

Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Tyrosine Allergoid Paediatric and Adult Study